Press releases
- Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024
- Insulet Appoints Ana Maria Chadwick as Chief Financial Officer
- Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy
- Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
- Insulet Reports Full Year 2023 Revenue Increase of 30% (30% Constant Currency¹) and Fourth Quarter 2023 Revenue Increase of 38% Year-Over-Year (37% Constant Currency)
- Insulet to Present at The Raymond James & Associates 45th Annual Institutional Investors Conference
- Insulet Announces CE Mark Approval of Omnipod® 5 Integration with Abbott FreeStyle Libre 2 Plus Sensor
- Imperative Care Announces Four Senior Leadership Appointments
More ▼
Key statistics
On Thursday, Insulet Corp (GOV:BRN) closed at 279.89, 0.00% below its 52-week high of 279.89, set on Apr 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 279.89 |
---|---|
High | 279.89 |
Low | 279.89 |
Bid | 281.93 |
Offer | 283.02 |
Previous close | 279.89 |
Average volume | -- |
---|---|
Shares outstanding | 70.02m |
Free float | 69.80m |
P/E (TTM) | 59.35 |
Market cap | 11.71bn USD |
EPS (TTM) | 2.82 USD |
Data delayed at least 15 minutes, as of Apr 27 2023.
More ▼